Surprisingly, ITZ total absorption to systemic compartment was lower for formulation F3 than for formulation F2 (plasmatic AUC0-24h of 491.5 ng h/mL and 376.8 ng h/mL for formulations F2 and F3, respectively). We assumed this lower plasmatic AUC0–24h for F3 was caused by an underestimation because of unsampled early time point (before 5 min) at which ITZ plasmatic concentrations values could have been higher than the first one measured 5 min post-administration due to very fast ITZ absorption from this formulation. Moreover, the high variability on mean concentration at this first sampling time (5 min, Fig. 6) could also have influenced downwards formulation F3’s AUC value. However, regarding the AUCplasma to AUClung ratio, which can be taken as the ITZ systemic bioavailability after pulmonary deposition of an inhaled substance[26], F3 seemed to offer a higher ITZ bioavailability from the lung than formulation F2 (Table 3).